Optibrium and Integrated Chemistry Design Collaborat?e to Introduce Creative Compound Design on iPad
Optibrium and Integrated Chemistry Design, providers of software solutions and services for drug discovery, have announed the release of Asteris, a new iPad app that combines highly intuitive chemistry drawing tools with the most visually informative predictive modelling. Asteris enables creative researchers to rapidly evaluate new compound ideas when and where they want, no longer limited to sitting in an office or in front of a computer.
Asteris uses Chirys Draw’s patent pending chemical drawing tools, optimised specifically for the touch environment, allowing users to explore a much wider range of chemistry designs. Instant feedback from StarDrop’s predictive models, guided by the unique Glowing Molecule visualisation, dramatically reduces the time required to identify high quality compound designs. With Asteris users can calculate a range of “core properties”, such as logP, molecular weight, polar surface area, and hydrogen bond donors, and predict over ten ADME properties, including solubility, hERG inhibition, and CNS penetration.
Dr Matthew Segall, Optibrium’s CEO, commented: “We are very pleased to be working with Integrated Chemistry Design. The combination of our unique technologies in Asteris provides an innovative ideas space, giving users the flexibility to explore new compound designs, beyond the constraints of traditional computational tools. This collaboration furthers our on-going strategy to work with other leading developers of innovative solutions for drug discovery.”
Dr M. Catherine Johnson, President and CEO of Integrated Chemistry Design added: “We are excited that Asteris provides medicinal chemists with powerful tools for evaluating prospective drug ideas, and they can use Asteris anywhere, in meetings or on travel as well as in their offices. Using Asteris, drug designers will be able to assess ideas more quickly to converge on the most promising candidates for further study.”
Asteris will be launched at the American Chemical Society Spring 2014 National Meeting & Expo in Dallas, Texas from 16–20 March (visit Optibrium, booth #1516) and Integrated Chemistry Design (booth #400) to see Asteris in action. From 16 March, Asteris can be downloaded from the App Store.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance